NCT07445022RecruitingPhase 4
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
A Prospective, Open-Label, Multicenter, Real-World Study to Evaluate the Efficacy and Safety of Tunlametinib in Patients With NRAS-Mutant Advanced Melanoma
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- First submitted
- 25 Feb 2026
- Start date
- Jan 2026
- Primary completion date
- Sept 2028
- Lead sponsor
- Fudan University
- Diseases
- Melanoma
- NCT number
- NCT07445022
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 110
- From Jan 2026 to the primary completion date, Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently participating in other clinical trials of drugs;
Other illness
- Other conditions deemed unsuitable for targeted therapy after multidisciplinary discussion;
- Other conditions considered inappropriate for inclusion by the investigator, such as familial or social factors that may affect the safety of the subject or the collection of data.
Other
- Patients who are pregnant or breastfeeding;
Who the study is looking for
- Aged ≥18 years (inclusive), male or female;
- Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma;
- Prior genetic testing results showing positive NRAS mutation;
- Patients who have failed prior anti-PD-1/PD-L1 therapy;
- Able to take oral medications;
- Voluntarily participate and sign the informed consent form, expected to have good compliance, and able to cooperate with the study according to the protocol requirements.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.